Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
John Newman’s rating is based on several positive indicators for Regeneron. The company reported strong sales for EYLEA and EYLEA HD, which exceeded expectations despite facing certain challenges, indicating a potential stabilization of the EYLEA franchise. Additionally, Regeneron is heavily investing in its in-house assets, particularly Lynozyfic for multiple myeloma, which is expected to significantly contribute to long-term revenue growth.
Furthermore, the growth in Dupixent revenues, driven by recent label expansions and its safety advantage over emerging competitors, further strengthens Regeneron’s market position. The company’s weight-loss program also shows promise, potentially offering a unique approach to addressing obesity-related comorbidities. These factors, combined with the anticipation of resolving delayed catalysts and the potential success of upcoming trials, support the Buy rating and the $850 price target for Regeneron.